Scott Williams

16.8k total citations · 6 hit papers
164 papers, 6.5k citations indexed

About

Scott Williams is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Radiation. According to data from OpenAlex, Scott Williams has authored 164 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Pulmonary and Respiratory Medicine, 57 papers in Radiology, Nuclear Medicine and Imaging and 34 papers in Radiation. Recurrent topics in Scott Williams's work include Prostate Cancer Treatment and Research (114 papers), Prostate Cancer Diagnosis and Treatment (99 papers) and Radiopharmaceutical Chemistry and Applications (35 papers). Scott Williams is often cited by papers focused on Prostate Cancer Treatment and Research (114 papers), Prostate Cancer Diagnosis and Treatment (99 papers) and Radiopharmaceutical Chemistry and Applications (35 papers). Scott Williams collaborates with scholars based in Australia, United States and Canada. Scott Williams's co-authors include Shahneen Sandhu, Michael S. Hofman, Declan G. Murphy, Gillian Duchesne, Rodney J. Hicks, Amir Iravani, John Violet, Grace Kong, Tim Akhurst and Sue Ping Thang and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Scott Williams

163 papers receiving 6.4k citations

Hit Papers

[177Lu]-PSMA-617 radionuclide treatment in patients with ... 2016 2026 2019 2022 2018 2016 2021 2018 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
    2018 815 citations Michael S. Hofman, John Violet et al. The Lancet Oncology profile →
  2. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study
    2016 419 citations John Yaxley, Geoffrey D. Coughlin et al. The Lancet profile →
  3. Prostate cancer
    2021 355 citations Shahneen Sandhu, Scott Williams et al. The Lancet profile →
  4. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
    2018 339 citations John Violet, Justin Ferdinandus et al. Journal of Nuclear Medicine profile →
  5. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study
    2018 281 citations Geoffrey D. Coughlin, John Yaxley et al. The Lancet Oncology profile →
  6. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
    2017 251 citations Oliver Sartor, Howard R. Soule et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Williams Australia 41 4.7k 2.3k 1.2k 1.0k 718 164 6.5k
R. Valdagni Italy 43 3.6k 0.8× 1.8k 0.8× 1.2k 1.0× 1.8k 1.7× 964 1.3× 242 6.6k
Jeffrey D. Forman United States 38 6.0k 1.3× 1.2k 0.5× 1.1k 0.9× 2.2k 2.1× 1.2k 1.6× 140 8.2k
Thomas Wiegel Germany 38 8.2k 1.7× 1.7k 0.7× 1.8k 1.5× 1.3k 1.3× 1.9k 2.6× 232 10.5k
Anders Widmark Sweden 43 4.2k 0.9× 981 0.4× 1.6k 1.3× 999 1.0× 1.1k 1.5× 173 7.2k
Raymond Miralbell Switzerland 49 4.5k 1.0× 2.1k 0.9× 981 0.8× 2.6k 2.5× 1.0k 1.4× 216 7.7k
Jeremy Millar Australia 37 3.8k 0.8× 768 0.3× 1.6k 1.3× 1.4k 1.4× 1.5k 2.1× 294 6.5k
Eric M. Horwitz United States 53 7.6k 1.6× 1.5k 0.6× 1.3k 1.0× 3.7k 3.6× 1.7k 2.3× 292 10.3k
В. Б. Матвеев Russia 22 6.1k 1.3× 992 0.4× 1.5k 1.2× 310 0.3× 1.2k 1.7× 184 7.4k
Nicolas Mottet France 36 6.8k 1.4× 1.4k 0.6× 1.6k 1.3× 328 0.3× 1.5k 2.0× 147 8.6k
Gregory P. Swanson United States 28 4.4k 0.9× 455 0.2× 620 0.5× 1.2k 1.2× 807 1.1× 138 5.6k

Countries citing papers authored by Scott Williams

Since Specialization
Citations

This map shows the geographic impact of Scott Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Williams more than expected).

Fields of papers citing papers by Scott Williams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Williams. The network helps show where Scott Williams may publish in the future.

Co-authorship network of co-authors of Scott Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Williams. A scholar is included among the top collaborators of Scott Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Williams. Scott Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eapen, Renu, Scott Williams, Sean Macdonald, et al.. (2024). Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. Nature Reviews Urology. 21(11). 676–686. 6 indexed citations
2.
3.
4.
Roberts, Matthew J., George Hruby, Andrew Kneebone, et al.. (2023). Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?. British Journal of Urology. 132(2). 146–148. 2 indexed citations
5.
Dhiantravan, Nattakorn, Louise Emmett, Anthony M. Joshua, et al.. (2021). UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol). British Journal of Urology. 128(3). 331–342. 40 indexed citations
6.
Haworth, Annette, Sun Yu, Scott Williams, et al.. (2021). Biologically Targeted Radiation Therapy: Incorporating Patient-Specific Hypoxia Data Derived from Quantitative Magnetic Resonance Imaging. Cancers. 13(19). 4897–4897. 9 indexed citations
7.
Sandhu, Shahneen, Anthony M. Joshua, Louise Emmett, et al.. (2021). 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 32. S626–S627. 14 indexed citations
8.
Keam, Simon P., Heloise M. Halse, Thu Quynh Nguyen, et al.. (2020). High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. Journal for ImmunoTherapy of Cancer. 8(1). e000792–e000792. 51 indexed citations
9.
Miyahira, Andrea K., Kenneth J. Pienta, John W. Babich, et al.. (2020). Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. The Prostate. 80(15). 1273–1296. 21 indexed citations
10.
Ferdinandus, Justin, John Violet, Shahneen Sandhu, et al.. (2020). Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging. 47(10). 2322–2327. 115 indexed citations
11.
Miyahira, Andrea K., Kenneth J. Pienta, Michael J. Morris, et al.. (2018). Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group. The Prostate. 78(11). 775–789. 32 indexed citations
12.
13.
Haworth, Annette, Sun Yu, Martin A. Ebert, et al.. (2018). Incorporating a Novel Radiomics Framework for Biologically Optimised Prostate RadioTherapy (BiRT). Medical Physics. 45(6). 3 indexed citations
14.
Coughlin, Geoffrey D., John Yaxley, Suzanne K. Chambers, et al.. (2018). Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. The Lancet Oncology. 19(8). 1051–1060. 281 indexed citations breakdown →
15.
Hofman, Michael S., et al.. (2018). A First-in-Human Study of 68Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways. Journal of Nuclear Medicine. 59(12). 1837–1842. 15 indexed citations
16.
Yaxley, John, Geoffrey D. Coughlin, Suzanne K. Chambers, et al.. (2016). Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. The Lancet. 388(10049). 1057–1066. 419 indexed citations breakdown →
17.
Haworth, Annette, John M. Betts, Hayley M. Reynolds, et al.. (2015). A radiobiology-based inverse treatment planning method for optimisation of permanent l-125 prostate implants in focal brachytherapy. Physics in Medicine and Biology. 61(1). 430–444. 14 indexed citations
18.
Taylor, Jeremy M. G., Yongseok Park, Donna P. Ankerst, et al.. (2013). Real‐Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models. Biometrics. 69(1). 206–213. 72 indexed citations
19.
Buyyounouski, Mark K., et al.. (2011). A Nomogram Predicting 5-year Probability of Cause Specific Survival from Biochemical Failure following Radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 81(2). S389–S389. 1 indexed citations
20.
Buyyounouski, Mark K., et al.. (2009). Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 75(3). S103–S104. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Valdagni Breakdown of academic impact, for papers by Jeffrey D. Forman Breakdown of academic impact, for papers by Thomas Wiegel Breakdown of academic impact, for papers by Anders Widmark Breakdown of academic impact, for papers by Raymond Miralbell Breakdown of academic impact, for papers by Jeremy Millar Breakdown of academic impact, for papers by Eric M. Horwitz Breakdown of academic impact, for papers by В. Б. Матвеев Breakdown of academic impact, for papers by Nicolas Mottet Breakdown of academic impact, for papers by Gregory P. Swanson
Rankless by CCL
2026